Vejle Sygehus

Running trials

• Not yet recruiting

  Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer

  NCT07903883· University of Aarhus· Source

• Not yet recruiting

  Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer

  2025-522431-34-00· Phase 2· Region Hovedstaden· Source

• Not yet recruiting

  Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies

  NCT07878208· Odense University Hospital· Source

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· CSL Behring· Source

• Not yet recruiting

  Examination of Rectal Blood Supply During Rectal Cancer Surgery Using Laser Speckle Contrast Imaging

  NCT07799740· University of Aarhus· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Source

• Enrolling by invitation

  MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease

  NCT06788340· Phase 4· Odense University Hospital· Source

• Recruiting

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· Phase 3· AstraZeneca· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Holistic Acupuncture for Patients With Chemotherapy Induced Nausea

  NCT07201194· Vejle Hospital· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

  NCT07048262· Phase 2· CSL Behring· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

  NCT07023289· Phase 2· AbbVie· Source

• Recruiting

  Prehabilitation to Patients With Prostate Cancer

  NCT07162987· Odense University Hospital· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Self-administration of Subcutaneous Elranatamab in the Patients' Homes.

  NCT06015542· Phase 2· Thomas Lund· Source

• Recruiting

  SMARTER: Using Blood Samples to iMprove FIT-bAsed coloRecTal cancEr scReening

  NCT06714318· Vejle Hospital· Source

• Active, not recruiting

  An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma

  2024-512113-41-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

  NCT06629779· Phase 3· Pfizer· Source

• Recruiting

  Understanding and Tailored Treatment of Low Anterior Resection Syndrome

  NCT07573371· Aalborg University Hospital· Source

• Recruiting

  Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

  NCT06505369· Phase 2· North Estonia Medical Centre· Source

• Active, not recruiting

  TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of first line treatment in transplant eligible multiple myeloma patients

  2023-508212-38-00· Phase 2· North Estonia Medical Centre Foundation· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  NCT06312176· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  VIsualization of Coronary Artery Disease for Modification of RISK Factors

  NCT06413641· Aarhus University Hospital· Source

• Active, not recruiting

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06191744· Phase 3· Genmab· Source

• Recruiting

  Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

  NCT06585007· Phase 3· Universitaire Ziekenhuizen KU Leuven· Source

• Active, not recruiting

  Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

  NCT05890729· Phase 1/2· Xentria, Inc.· Source

• Active, not recruiting

  A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  NCT05936359· Phase 1· Incyte Corporation· Source

• Active, not recruiting

  Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)

  2022-500100-21-01· Phase 2· Oslo University Hospital Hf· Source

• Recruiting

  NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer

  NCT05572801· Aarhus University Hospital· Source

• Recruiting

  DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies

  NCT06076811· University of Aarhus· Source

• Active, not recruiting

  The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

  NCT03129490· Phase 4· Herlev and Gentofte Hospital· Source

• Active, not recruiting

  A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05572515· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

  NCT05624554· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer

  NCT05810701· Odense University Hospital· Source

• Recruiting

  A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05552222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)

  NCT05444348· Christoffer Johansen· Source

• Recruiting

  Prevention of Oxaliplatin-induced Nerve Damage in the Body's Extremities

  NCT05404230· Vejle Hospital· Source

• Recruiting

  Navigate - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients

  NCT05053997· Zealand University Hospital· Source

• Active, not recruiting

  Protons vs. Photons for High-risk Prostate Cancer

  NCT05350475· University of Aarhus· Source

• Active, not recruiting

  Shared Decision Making on Radiation Dose for Lung Malignancies

  NCT04940936· Vejle Hospital· Source

• Active, not recruiting

  A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04628494· Phase 3· Genmab· Source

• Active, not recruiting

  A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

  NCT04607421· Phase 3· Pfizer· Source

• Recruiting

  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  NCT04613596· Phase 2/3· Mirati Therapeutics Inc.· Source

• Active, not recruiting

  Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

  NCT04623541· Phase 1/2· Genmab· Source

• Active, not recruiting

  Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

  NCT04663347· Phase 1/2· Genmab· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

  NCT04497844· Phase 3· Janssen Research & Development, LLC· Source

Showing 50 of 64.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer11 recruiting
• Lung cancer5 recruiting
• Multiple myeloma5 recruiting
• Ovarian cancer3 recruiting
• Prostate cancer3 recruiting
• Crohn's disease2 recruiting
• Obesity2 recruiting
• Pancreatic cancer2 recruiting
• Ulcerative colitis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Bronchiectasis1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• COPD1 recruiting
• Cystic fibrosis1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Heart failure1 recruiting
• Hodgkin lymphoma1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Sarcoidosis1 recruiting

Closed trials

• Completed

  A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  2022-502457-34-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

  NCT06169397· Phase 2· Xentria, Inc.· Source

• Completed

  Subcutaneous immunoglobulin (HyQvia) against early infections in multiple myeloma: SHIELD

  2023-505053-40-00· Phase 2· Lillebaelt Hospital· Source

• Completed

  MRI T1 Relaxation Time in Rectal Cancer

  NCT05876026· Vejle Hospital· Source

• Completed

  Spinal Anaesthesia vs. General Anaesthesia for THA, TKA and UKA

  NCT05706844· Phase 4· Anders Troelsen· Source

• Completed

  Clinical trial on Spinal Anaesthesia vs. General Anaesthesia (SAGA) on recovery after hip and knee replacements

  2022-501221-21-00· Phase 4· Hvidovre Hospital· Source

• Completed

  Implementation of Smoking Cessation Support During Lung Cancer Workup

  NCT05192031· Vejle Hospital· Source

• Completed

  A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

  NCT05071664· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

  NCT04776148· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

  NCT04472429· Phase 3· Incyte Corporation· Source

• Completed

  Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  NCT04191616· Phase 2· Amgen· Source

• Completed

  Single-stapled Double Purse-string Technique for Colorectal Anastomosis

  NCT04223141· Vejle Hospital· Source

• Completed

  Registry of Asthma Patients Initiating DUPIXENT®

  NCT04287621· Regeneron Pharmaceuticals· Source

• Completed

  Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

  NCT04175470· Phase 2· Vejle Hospital· Source

• Active, not recruiting

  A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

  NCT04008030· Phase 3· Bristol-Myers Squibb· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Stemline Therapeutics, Inc.· Source

• Active, not recruiting

  A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

  NCT03539744· Phase 3· AbbVie· Source

• Completed

  Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

  NCT03562832· Phase 2· Allarity Therapeutics· Source

• Completed

  Prevention of Chest Pain in Chemo-treated Cancer Patients

  NCT03486340· Vejle Hospital· Source

• Completed

  Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· pharmaand GmbH· Source

• Completed

  Quality of Life the Danish Multiple Myeloma Patients

  NCT02892383· Odense University Hospital· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· German CLL Study Group· Source

• Completed

  Shared Decision Making With Anal Cancer Patients on Radiation Dose

  NCT02785263· Vejle Hospital· Source

• Completed

  Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer

  NCT02705300· Phase 2· Vejle Hospital· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source